Table 7.
Cut-off of 90% sensitivity of the markers in subjects with tPSA 4–10 ng/mL
| Marker | Cut-off at 90% sensitivity | % Specificity | Unnecessary biopsy avoided | Missed cancer | |||
|---|---|---|---|---|---|---|---|
| Total | Missed GS 6 | Missed GS 7 | Missed GS ≥ 8 | ||||
| Total PSA 4–10 ng/mL | |||||||
| %fPSA | ≤ 7.86 | 9% |
4 (5.2%) |
3 (10.3%) |
0 (0%) |
1 (3.5%) | 2 (6.8%) |
|
p2PSA (pg/mL) |
≥ 8.08 | 17% |
7 (9.1%) |
3 (10.3%) |
2 (6.8%) |
0 (0%) |
1 (3.5%) |
|
% p2PSA |
≥ 1.20 | 27% |
12 (15.5%) |
3 (10.3%) | 3 (10.3%) |
0 (0%) |
0 (0%) |
| PHI | ≥ 26.33 | 25% |
9 (11.7%) |
2 (6.8%) |
2 (6.8%) |
0 (0%) |
0 (0%) |
| All study subjects | |||||||
| %fPSA | ≤ 6.42 | 7% |
6 (4.3%) |
7 (11.1%) |
0 (0%) |
2 (3.2%) | 5 (7.9%) |
|
p2PSA (pg/mL) |
≥ 8.07 | 20% |
16 (11.4%) |
7 (11.1%) |
4 (6.3%) |
2 (3.2%) | 1 (1.6%) |
|
% p2PSA |
≥ 1.22 | 31% |
24 (17.1%) |
7 (11.1%) | 7 (11.1%) |
0 (0%) |
0 (0%) |
| PHI | ≥ 33.40 | 40% |
32 (22.9%) |
5 (7.9%) |
5 (7.9%) |
0 (0%) |
0 (0%) |
PSA, prostate-specific antigen; fPSA, free PSA; p2PSA, [-2]proPSA; PHI, prostate health index
Bold types to represent clinical significance could avoid unnessasary biopsies for %p2SPA and PHI